HWM
VKTX icon

HB Wealth Management’s Viking Therapeutics VKTX Stock Holding History

HB Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
12,907
+1,951
+18% +$63K ﹤0.01% 1110
2026
Q1 		$357K Buy
10,956
+246
+2% +$7.91K ﹤0.01% 1123
2025
Q4 		$377K Buy
+10,710
New +$379K ﹤0.01% 1028

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HB Wealth Management's VKTX Position: Q2 2026 in Review

HB Wealth Management increased its Viking Therapeutics (VKTX) stake by 18% in Q2 2026, buying an estimated $63K and bringing the position to 12,907 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

HB Wealth Management first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HB Wealth Management held 12,907 shares of Viking Therapeutics worth $504K as of Q2 2026.
  • HB Wealth Management bought 1,951 Viking Therapeutics shares in Q2 2026, an estimated $63K.
  • Viking Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1110 holding.
  • HB Wealth Management first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.